Graphene Oxide Deemed Safe in First Human Clinical Trial
A landmark study reveals that controlled inhalation of ultra-pure graphene oxide poses no short-term health risks, paving the way for its broader application in medical and technological fields.
- The study, a collaboration between the Universities of Edinburgh and Manchester, marks the first controlled human exposure to graphene oxide.
- Volunteers showed no adverse effects on lung function, blood pressure, or cardiovascular health after inhaling the material.
- Researchers observed a minor change in blood clotting, but emphasized its insignificance.
- Further research is needed to assess the effects of longer exposure and different forms of graphene.
- The findings could lead to the development of new medical treatments and devices, with minimal risk to human health.
Interesting Engineering 
Evening Standard 